Goals: We analyzed the rates of LDL-C testing within 6 months and LDL-C goal attainment (<70 mg/dL) in a cohort of patients undergoing CAD or PAD revascularization. Methods: We retrospectively analyzed 8,172 patients from a large health network who underwent percutaneous coronary intervention ...
Although statin monotherapy could reduce LDL-C levels to a large extent (up to À50% with the highest doses of most potent statins), this might not be enough to reach the desired goals based on the individual CV risk, and therefore additional approaches are needed. This is even more ...
The objective of the present study was to investigate the prevalence of elevated Lp(a) levels in a population of patients with CAD and how they impact LDL-C concentrations and the achievement of the LDL-C goals set forth in the guidelines for very high-risk CAD patients. ...
“The task force is aware of the limitations of some of the sources of evidence and accepts that randomized, controlled trials have not examined different LDL-cholesterol goals systematically, but felt that it was appropriate to look at the totality of the evidence,” states the ESC/EA...
The European Society of Cardiology (ESC)/European Society of Atherosclerosis (EAS) has defined low-density lipoprotein cholesterol (LDL-C) goals according to the patient's cardiovascular (CV) risk, with no specific recommendations concerning sex [2]. Women are less likely to be diagnosed ...
No. (%)Median Follow-up, yMore Intensive LDL-C LoweringLess Intensive LDL-C Lowering WomenHistoryTreatmentBaseline LDL-C, Mean (SD), mg/dLLDL-C Reduction, %TreatmentBaseline LDL-C, Mean (SD), mg/dLLDL-C Reduction, % DiabetesVascular DiseaseCAD 4S, 1994 4444 827 (19) 202 (5) 4444 ...
Multiple-drug therapy of dyslipidemia is frequently used to achieve treatment goals in high-risk patients with coronary artery disease. The authors report a case of a patient treated with a statin, fibrate, ezetimibe, and niacin in whom a calculated low-density lipoprotein cholesterol level of 5 ...
Human association studies to date have been conflicting regarding whether polymorphisms in this gene are associated with CAD and/or its complications [13–21]. As part of the overall goals of theAtheroscleroticDisease,VAscular FuNction, & GenetiC Epidemiology (ADVANCE) study at Stanford University and...
LDL-C is the focus for the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) [1] guidelines, which suggest treatment goals and cut-off LDL-C levels for initiating intervention. While LDL-C is a proven causative agent for CAD, the search continues for additional ...
stringent goals for the lowering of LDLlevels in primary and secondary coronary prevention.[14,15] Among other guideline changes, th Adult Treatment Panel (ATP) III[15] extended the LDL-C goal of < 100 mg/dL (previously forpatients with es...